论文部分内容阅读
我们观察了32例应用干扰素治疗的慢性乙型肝炎(CHB)患者的干扰素抗体(抗-IFN),以了解抗-IFN的检测在干扰素治疗中的意义。1 资料与方法1.1 病例选择:CHB32例中,男29例,女3例,年龄21岁～53岁。轻型18例,中型14例,均为我院住院及门诊患者。诊断符合1995年北京修订《病毒性肝炎防治方案》标准。检测HBsAg、HBeAg、抗-HBc、HBV-DNA均为阳性,并排除甲型、丙型、戊型肝炎病毒感染。所有患者治疗前均未受过α-干扰素治疗。1.2 治疗方法:采用基因工程干扰素α-1b(赛若金)治疗,剂
We observed the interferon antibodies (anti-IFN) in 32 patients with interferon-treated chronic hepatitis B (CHB) to understand the significance of anti-IFN detection in interferon therapy. 1 Materials and Methods 1.1 Case Selection: CHB32 cases, 29 males and 3 females, aged 21 to 53 years. 18 cases were light and 14 cases were medium-sized, all of whom were hospitalized and outpatient in our hospital. Diagnosis in line with the 1995 revision of Beijing’s “viral hepatitis prevention and control programs” standard. Detection of HBsAg, HBeAg, anti-HBc, HBV-DNA were positive, and rule out the A, C and E hepatitis virus infection. All patients had not been treated before interferon α-interferon. 1.2 Treatment: The use of genetic engineering interferon α-1b (Sauron gold) treatment, agent